Do you know that younger people are becoming cancer patients? How to avoid this deadly disease? Intake of ultra-processed foods, obesity, microbial toxins and exposure to chemicals are considered risk factors, and accumulation of these factors causes cancer. Although more than 9,000 cases of cancer are diagnosed each day in adults under the age of 50, a clear answer remained elusive.
Researchers worldwide are confronting a troubling epidemiological shift: cancers long considered diseases of aging are increasingly being diagnosed in adults under 50. This phenomenon, known as early-onset cancer (EAOC), has sparked urgent investigations into its causes. Interested readers can also read about melanoma, leukemia, sarcoma, and carcinoma cancers.
While genetic predisposition accounts for some cases, approximately 20% of early-onset colorectal cancers (EOCRC) occur in individuals with family history; the majority appear sporadic and likely originate from modern environmental and lifestyle factors. This report synthesises current evidence on detection challenges, specific cancer trends, environmental exposures, metabolic links, and emerging treatments to provide a comprehensive overview of this growing health crisis.
Is There a Problem with the Detection of Cancer?
The rising incidence of EAOC presents a significant detection paradox. While improved screening and diagnostic technologies have increased cancer detection, this does not fully explain EAOC trends. Research published in Cancer Research (2025) employed mathematical modelling to distinguish between apparent increases (earlier detection) and true increases (actual rising risk).
It has been found that accelerated carcinogenic events and shorter stopover times, the interval from first malignant cell emergence to clinical detection, in more recent birth cohorts for breast, colorectal, and thyroid cancers, support true risk increases. For example, childhood exposure to mutagen-producing bacteria contributes to lifetime colorectal cancer risk by imprinting oncogenic mutations in the developing colorectal epithelium long before diagnosis (See the report by Alexandrov et al. 2026 for details)
However, substantial barriers to timely detection persist. A 2024 symposium on EAOC identified critical gaps: limited public and healthcare provider awareness of cancer symptoms in younger adults, exclusion of younger populations from standard screening programs, and diagnostic delays. Most countries begin colorectal cancer screening at age 45-50, leaving younger individuals to be diagnosed only after symptom development, often at advanced stages. The symposium generated calls to re-evaluate screening eligibility criteria and reduce waiting times for diagnostic testing.
Why Is Colorectal Cancer Increasing Among 20-49-Year-Old People?
Colorectal cancer (CRC) has become the most concerning example of the EAOC phenomenon. In the United States, CRC is now the leading cause of cancer death in men under 50 and the second leading cause in women of the same age group. Globally, the incidence of EOCRC increased by approximately 1.73% annually between 1990 and 2019, surpassing stomach cancer as the most common early-onset digestive system cancer.
Trends in colon cancer
Though colon cancer is increasing, the trend is not confined to Western nations. A comprehensive analysis of 50 countries revealed that early-onset colon cancer rates are rising in over 40 countries, with 35 countries showing either increasing rates in younger populations alongside decreasing rates in older adults, or more rapid increases in the young.
Race/location specificity of rectal cancer
Singapore-specific data demonstrates particularly sharp rises in rectal cancer among Malay and Chinese populations, with the 1980-1984 birth cohort showing a 35% higher incidence rate ratio for rectal cancer compared to the 1950-1954 reference cohort.
Biological characteristics and colon cancer
EOCRC also exhibits distinct biological characteristics. Although tumours are more frequently located in the left colon or rectum, they are more often poorly differentiated and diagnosed at later stages than late-onset CRC. Despite this aggressive presentation, younger patients paradoxically show better cancer-specific survival after adjusting for stage, likely due to fewer comorbidities and better treatment tolerance.
Is the Uterine Cancer Birth Cohort Effect?
Yes, compelling evidence supports a birth cohort effect for uterine (endometrial) cancer. Analysis of Global Burden of Disease 2021 data using age-period-cohort (APC) models, which separate the influence of aging from temporal period and generational cohort effects, reveals that uterine cancer incidence has increased progressively in more recent birth cohorts.
The cohort effect represents differences across groups born in the same period due to shared generational experiences. For uterine cancer, women born after 1970 show higher relative risks compared to those born mid-century. This pattern mirrors trends observed for breast and ovarian cancers, where recent birth cohorts also demonstrate slight but significant increasing tendencies.
The above-stated generational patterns suggest that exposures during early life or reproductive years, including dietary changes, environmental chemicals, and obesity trends, have cumulatively increased cancer susceptibility across successive generations. For colorectal cancer, Singapore data similarly showed that rectal cancer incidence peaked in the 1980-1984 birth cohort before moderating.
How Does Environmental Exposure Increase the Risk of Cancer Development?
Environmental exposures, particularly to endocrine-disrupting chemicals (EDCs), represent a critical but underappreciated risk factor for EAOC. These compounds interfere with hormonal regulation, immune function, and metabolic processes.
A 2025 review in iScience established that polycyclic aromatic hydrocarbons (PAHs) from fossil fuels can initiate breast cancer in animal models, with human evidence supporting a link between PAH exposure and breast cancer risk.
Effect of exposure window
The exposure window to environmental hazards matters tremendously. It takes approximately two decades for PAH-exposed breast cells to progress to diagnosable cancer, and susceptibility is heightened by in utero exposure through pregnant mothers to environmental pollutants or maternal obesity.
The early-life exposures increase breast cancer susceptibility by increasing target cell populations, suppressing DNA repair mechanisms (potentially via epigenetic changes), and inducing persistent gut dysbiosis.
Habit of taking ultra-processed foods
Ultra-processed foods (UPFs) act as Trojan horses for EDCs. Bisphenols and phthalates migrate from plastic packaging into foods, while additives and high-temperature processing generate additional compounds. A comprehensive 2025 review in Cancers argues that UPFs deliver these biologically active compounds while simultaneously promoting chronic inflammation, altering gut microbiota, and inducing epigenetic changes, creating a permissive environment for carcinogenesis.
How Metabolic Disease and Obesity Are Related to Cancer Development at a Younger Age
The parallel rise in early-onset cancer and metabolic diseases among young populations is unlikely coincidental. A 2025 Nature Reviews Endocrinology review synthesises evidence that obesity and type 2 diabetes mellitus (T2DM) contribute to EOCRC through multiple mechanisms: insulin resistance and hyperinsulinemia (which promote cellular proliferation), chronic inflammation (the "seventh hallmark of cancer"), and altered gut microbiome composition.
Global trends in obesity and cancer
Global obesity trends are staggering: adult obesity more than doubled between 1990 and 2022, while adolescent obesity quadrupled, increasing faster among young people than adults. High body-mass index is the leading risk factor for uterine cancer, contributing to higher disease burden in higher socioeconomic development index regions. For breast cancer, high red meat consumption joins high BMI as a leading attributable risk factor.
Metabolic-carcinogenesis link with cancer
A 2025 analysis using age-period-cohort models showed that the age-specific incidence rates of breast and cervical cancers are increasing rapidly in young age groups, with positive estimated annual percentage changes. This metabolic-carcinogenesis link suggests that interventions targeting obesity, including GLP-1 receptor agonists and metformin, may reduce the risk of EAOC, although long-term efficacy requires further study.
Role of Ultra-Processed Foods on Cancer Development
The global surge in UPF consumption, now comprising over 50% of daily calories for many adolescents in the US and UK, parallels EAOC trends. Beyond poor nutrition, UPFs contribute to cancer through three primary pathways:
Endocrine disruption
The processing of substances creates and releases endocrine-disrupting chemicals (EDCs) that can interfere with hormonal signalling. These compounds pose a heightened risk during key stages of development, such as in the womb, childhood, and adolescence, when the endocrine system is still maturing.
Chronic inflammation
UPF components promote low-grade systemic inflammation, a known tumour promoter. The Trojan horse model describes how UPFs appear harmless while silently dysregulating immune function.
Microbiome alteration
UPFs disrupt gut microbial communities, reducing beneficial bacteria and promoting dysbiosis. This alteration increases intestinal permeability, allows bacterial toxins to enter circulation, and creates a pro-inflammatory, pro-carcinogenic environment.
Specific dietary factors identified as EOCRC risk factors include Western dietary patterns, sugar-sweetened beverages, red and processed meat, and low intake of fibre, vegetables, fruits, and calcium.
How Do Microorganisms Influence Colorectal Cancer Development?
The gut microbiome sits at the intersection of diet, metabolism, and cancer. Chronic inflammation from microbial dysbiosis can promote tumorigenesis. Patients with inflammatory bowel disease have nearly a threefold higher risk of developing CRC at an earlier age.
Microbes involved with cancer development
Key microorganisms for cancer development include Human Papillomavirus (HPV), Helicobacter pylori, Hepatitis B and C, Epstein-Barr Virus, Fusobacterium nucleatum, and Fungi. Research has identified specific microbial signatures associated with CRC, including Fusobacterium nucleatum, which appears to promote tumour progression and chemotherapy resistance. Conversely, certain beneficial bacteria may protect against CRC by producing short-chain fatty acids (such as butyrate) that maintain gut barrier integrity, regulate immune responses, and induce apoptosis in damaged cells.
Diet and microbial composition
The microbiome acts as a dynamic living sensor of lifestyle changes. Western diets high in fat and low in fibre rapidly alter microbial composition, reducing diversity and favouring pro-inflammatory species. This diet-microbiome-cancer axis represents a modifiable target for prevention: dietary modifications that enhance beneficial gut bacteria could potentially mitigate CRC risk.
Continent-Wise Deaths of People Because of Cancer
Global cancer mortality data from 2021 show breast cancer contributed the highest number of female cancer deaths worldwide (~1.22 million total female cancer deaths), followed by cervical, uterine, and ovarian cancers. However, significant regional variation exists. Age-standardised mortality rates (ASMR) for cervical cancer decreased globally (EAPC = -1.38) between 1990 and 2021, but mortality remains highest in low-resource regions with poor screening access. Look at the figure below for continent-wise mortality of young people.
WP = Western Pacific Region, EU = Europe, AM = Region of the Americas, SE = Southeast Asia, and AF = Africa
For early-onset cancers specifically, mortality is higher in low-income countries despite lower incidence, reflecting inequalities in healthcare availability and treatment access. In high-income countries, CRC mortality in older adults has declined due to screening, while early-onset CRC mortality has not seen equivalent improvements. Comprehensive continent-specific five-year trends require further disaggregated data, but the pattern is clear: low and middle-income countries bear a disproportionate mortality burden from preventable and treatable cancers.
The Latest Advancement in Cancer Treatment
Recent breakthroughs offer hope for improving EAOC outcomes. The 2025 American Association for Cancer Research (AACR) meeting highlighted several paradigm-shifting advances:
Immunotherapy breakthroughs
A landmark phase 2 trial of dostarlimab in mismatch repair-deficient (dMMR) solid tumours achieved 82% complete response among evaluable patients and 92% recurrence-free survival at 2 years, allowing many patients to avoid surgery entirely. This is particularly relevant for early-onset gastrointestinal cancers.
Novel targeted therapies
SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy, produced complete remissions in relapsed/refractory acute myeloid leukemia. CHS-114, targeting CCR8-positive regulatory T cells, shows promise for reprogramming the tumour microenvironment in head-and-neck cancers.
RAS inhibition
After decades of considering KRAS "undruggable," RAS(ON) inhibitors are entering clinical development, offering hope for KRAS-mutant lung, colorectal, and pancreatic cancers.
Therapeutic vaccines
An immunomodulatory vaccine that reshapes immune responses against existing cancers is advancing to phase 3 trials.
These advances suggest a future where immunotherapy-first strategies may offer curative outcomes without traditional treatment morbidity.
Conclusion
The rising incidence of early-onset cancers represents a multifactorial crisis driven by Westernised diets, ultra-processed food consumption, obesity, environmental chemical exposures, and resulting microbial and metabolic dysregulation. True risk increases have been confirmed for colorectal, breast, and thyroid cancers, with cohort effects evident for several malignancies.
Addressing this crisis requires re-evaluating screening guidelines, reducing environmental toxin exposure, promoting metabolic health from early life, and leveraging emerging immunotherapies. Public health strategies must target generational risk factors to reverse these alarming trends.